Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
(2015) In BMC Clinical Pathology 15.- Abstract
- The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7477960
- author
- Gustbée, Emma ; Tryggvadottir, Helga LU ; Markkula, Andrea LU ; Simonsson, Maria LU ; Nodin, Björn LU ; Jirström, Karin LU ; Rose, Carsten LU ; Ingvar, Christian LU ; Borgquist, Signe LU and Jernström, Helena LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BMC Clinical Pathology
- volume
- 15
- article number
- 8
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:26109908
- pmid:26109908
- scopus:84929991987
- wos:000360473100001
- ISSN
- 1472-6890
- DOI
- 10.1186/s12907-015-0008-2
- language
- English
- LU publication?
- yes
- id
- 6fa86209-d806-44ce-bce0-6277f43f3b19 (old id 7477960)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26109908?dopt=Abstract
- date added to LUP
- 2016-04-01 12:58:54
- date last changed
- 2024-01-09 04:54:16
@article{6fa86209-d806-44ce-bce0-6277f43f3b19, abstract = {{The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).}}, author = {{Gustbée, Emma and Tryggvadottir, Helga and Markkula, Andrea and Simonsson, Maria and Nodin, Björn and Jirström, Karin and Rose, Carsten and Ingvar, Christian and Borgquist, Signe and Jernström, Helena}}, issn = {{1472-6890}}, language = {{eng}}, publisher = {{BioMed Central (BMC)}}, series = {{BMC Clinical Pathology}}, title = {{Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.}}, url = {{https://lup.lub.lu.se/search/files/3086931/8841235}}, doi = {{10.1186/s12907-015-0008-2}}, volume = {{15}}, year = {{2015}}, }